中国现代医学杂志2025，Vol.35Issue(15)：1-6,6.DOI:10.3969/j.issn.1005-8982.2025.15.001
德谷胰岛素利拉鲁肽注射液联合骨化三醇治疗糖尿病肾病的临床研究
Clinical study on the combination of insulin degludec/liraglutide and calcitriol in the treatment of diabetic nephropathy
摘要
Abstract
Objective To investigate the clinical efficacy and safety of insulin degludec/liraglutide(IDegLira)combined with calcitriol in diabetic nephropathy(DN).Methods DN patients were randomized into three groups:Control(n=53,calcitriol+insulin degludec),Experimental(n=56,IDegLira alone),and Combination(n=54,IDegLira+calcitriol).Efficacy,changes in glycemic control(HbA1c,FBG,2 hPG),inflammatory markers(CRP,PCT,VEGF,TGF-β1),renal function(β2-MG,BUN,Scr),and adverse events after 3 months were compared.Results The magnitude of improvement in HbA1c,FBG,and 2 hPG was significantly greater in the Experimental and Combination groups than in the Control group(P<0.05),but similar between Experimental and Combination groups(P>0.05).The magnitude of reduction in CRP,PCT,VEGF,and TGF-β1 was significantly greater in the Combination group than in the Experimental and Control groups(P<0.05),and greater in the Control than Experimental group(P<0.05).The magnitude of reduction in β2-MG,BUN,and Scr was significantly greater in the Combination group than in the Experimental and Control groups(P<0.05),but similar between Control and Experimental groups(P>0.05).The total effective rate was significantly higher in the Combination group than in the other groups(P<0.05).The incidence of hypoglycemia was significantly lower in the Experimental and Combination groups than in the Control group(P<0.05).Rates of nausea/vomiting/diarrhea were comparable.Conclusion IDegLira combined with calcitriol improves glycemic control,reduces inflammation,enhances renal function,and lowers hypoglycemia risk in DN patients compared to insulin degludec plus calcitriol or IDegLira alone.关键词
糖尿病肾病/德谷胰岛素利拉鲁肽/骨化三醇/临床疗效/安全性评价Key words
diabetic nephropathy/insulin degludec/liraglutide/calcitriol/clinical efficacy/safety evaluation分类
医药卫生引用本文复制引用
杨菲,袁媛..德谷胰岛素利拉鲁肽注射液联合骨化三醇治疗糖尿病肾病的临床研究[J].中国现代医学杂志,2025,35(15):1-6,6.基金项目
河北省卫生健康委员会医学科学研究课题计划项目(No:20220970) （No:20220970）
